Hsbc Global Res Upgrades Qiagen (NYSE:QGEN) to Hold

Qiagen (NYSE:QGENGet Free Report) was upgraded by analysts at Hsbc Global Res to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a report on Thursday, June 27th. Finally, HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Qiagen presently has a consensus rating of “Moderate Buy” and an average target price of $50.12.

Get Our Latest Research Report on Qiagen

Qiagen Stock Up 0.7 %

QGEN stock opened at $43.00 on Thursday. Qiagen has a 12-month low of $34.74 and a 12-month high of $47.44. The company has a quick ratio of 1.46, a current ratio of 1.77 and a debt-to-equity ratio of 0.27. The company has a market cap of $9.81 billion, a price-to-earnings ratio of 143.07, a PEG ratio of 3.36 and a beta of 0.39. The company has a 50 day moving average of $45.10 and a two-hundred day moving average of $43.52.

Qiagen (NYSE:QGENGet Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $496.00 million for the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. Qiagen’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the firm earned $0.53 EPS. On average, equities analysts anticipate that Qiagen will post 2.15 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its position in Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after purchasing an additional 500 shares during the last quarter. Riverview Trust Co acquired a new stake in Qiagen in the 1st quarter worth $28,000. Toronto Dominion Bank acquired a new stake in Qiagen in the 2nd quarter worth $27,000. Park Place Capital Corp acquired a new stake in Qiagen in the 1st quarter worth $36,000. Finally, Massmutual Trust Co. FSB ADV grew its position in Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

(Get Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

See Also

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.